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A COMPARISON OF NON-RESPONDER IMPUTATION AND LAST-OBSERVATION-
CARRIED-FORWARD ANALYSIS METHODS IN RHEUMATOID ARTHRITIS
CLINICAL TRIALS
Roy S, Chen N, Cifaldi M
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To highlight the importance and impact of imputation approach
used in reporting rheumatoid arthritis (RA) clinical trial results when data are
analyzed using non-responder imputation (NRI) versus last observation carried
forward (LOCF). METHODS: Non-responder imputation is a conservative analysis
method in which participant dropouts are assumed to be non-responders regard-
less of actual response status at the time of dropout. Last observation carried
forward is an analysis method in which the last measured value of a variable, such
as treatment response, is carried forward and assumed to be valid for a future point
of analysis. Results at 52weeks from the PREMIER trial, a double-blind, randomized
trial in adult patients with early RA (3 years) that compared among adalimumab
plus methotrexate (ADAMTX) and monotherapies with either drug were com-
pared using NRI and LOCF analyses. Outcomemeasures presented here are Amer-
ican College of Rheumatology (ACR) 50%, and 70% responses, and remission based
on 28-joint Disease Activity Score (DAS282.6). RESULTS: In the ADAMTX treat-
ment group, outcomemeasures calculated using NRI and LOCF, respectively, were
62% and 68% for ACR50, 46% and 48% for ACR70, and 43% and 47% for remission. In
the MTX-monotherapy group, NRI and LOCF values, respectively, were 46% and
49% for ACR50, 28% and 29% for ACR70, and 21% and 22% for DAS28 2.6. For all
outcomemeasures, the estimate of drug effect was lesser when using NRI analysis
compared with LOCF analysis. CONCLUSIONS: Non-responder imputation analy-
ses tend to result in more conservative estimates of drug effect on outcome mea-
sures than LOCF analyses. In trials in which there are high numbers of participant
dropouts, the difference in results using NRI versus LOCF could be substantial.
Thus, caution is warranted in comparisons of results across clinical trials using
these different imputation methods.
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COMPARISON OF PROPENSITY SCORE MATCHING AND INSTRUMENTAL
VARIABLE METHODS WHEN ESTIMATING HEALTH CARE COSTS OF
RHEUMATOID ARTHRITIS PATIENTS
Baser O, Xie L, Wang L, Du J
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES:To compare the two risk adjustmentmodelswhen estimating health-
care costs of rheumatoid arthritis (RA) patients. METHODS: Continuously eligible
adult patients with confirmed diagnoses of RA between June 2004 and June 2009
were included. Patients were new to tumor necrosis factor (TNF) therapy and sub-
sequently either switched to another anti-TNF or escalated their dose. The differ-
ence in total health care costs and RA-related health care costs between switchers
and escalators 1 year after the switch/escalation were estimated using the propen-
sity score matching and instrumental variable methods. When using propensity
score matching, the differences in patient, clinical, cost and utilization character-
istics during the baseline period were controlled. When using the instrumental
variable method, patients’ copayment, distance from patient to provider, and doc-
tors’ prescribing patterns were used as instruments to estimate the outcomes,
while other differences in patient and clinical characteristics were controlled as
well. RESULTS: After risk adjustment using propensity score matching, the differ-
ence between switchers and escalators is $648 in total healthcare costs, and $245 in
RA-related health care costs. After using the instrumental variable method, the
difference between switchers and escalators is $2054 in total health care costs and
$2809 in RA-related health care costs. CONCLUSIONS: After adjusting for patient,
clinical and demographic characteristics, the choice of risk adjustment method
affected the results. In this study, the cost burden is higher for switchers when
using the instrumental variable method as the risk adjustment technique.
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SUITABILITY OF THE EFFICIENCY FRONTIER APPROACH FOR THE EVALUATION
OF BIOLOGICAL AGENTS IN THE TREATMENT OF EARLY RHEUMATOID
ARTHRITIS
Gissel C, Repp H, Goetz G
Justus Liebig University Giessen, Giessen, Hessen, Germany
OBJECTIVES: The three most important biological agents adalimumab, etanercept
and infliximab caused €940mn drug expenditure at a 23% annual growth rate for
theGermanStatutoryHealth Insurance funds in 2009. The objective of this analysis
is to test the suitability of IQWiG’s efficiency frontier (EF) method for pharmaco-
economic analysis of biological agents in the treatment of early rheumatoid
arthritis.METHODS:Weapply simplified versions of the EF to infliximab. Effective-
ness analysis is based on the two year findings of the BeSt trial. It was identified as
the only trial to compare an active infliximab strategy to active conventional strat-
egies includingmultiple disease-modifying anti-rheumatic drugs (DMARDS). In the
first scenario, the analysis is conducted for the complete patient base. In the second
scenario, the evaluation is limited to patients, who are resistant to conventional
DMARD therapy. RESULTS: For the first scenario, effectiveness was measured in
terms of patient response defined as a sustained DAS44 score 2.4 after two years.
The EF was constructed with the best conventional alternatives, methotrexate
monotherapy and initial combination therapy with methotrexate, sulfasalazine
and prednisone. They achieved 33% and 58% response at €230 and €790 cumulative
expenditure. Infliximab was superior in patient response with 72% but caused
3€0,640 cumulative drug costs. IQWiG’s approach yields inefficiency of infliximab
since it is located to the right of the EF. In the second scenario, infliximab is not
comparable to conventional DMARDs with the EF approach. CONCLUSIONS: Our
analysis calls for cautious application of the EF method. Depending on the setup,
the EF may fail to recognize the value of highly innovative but expensive drugs for
a specific patient subgroup. In the case ofmissing conventional alternatives, the EF
yields no global measure of efficiency for comparisons across indications. There-
fore, complementary methods like IQWiG’s budget impact analysis are required.
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PATIENT-CENTRIC OBSERVATIONAL STUDY ON CORRELATES OF INTENT TO
PERSIST WITH TREATMENT: A REGRESSION MODEL IN OSTEOPOROSIS
Horowicz-Mehler N1, Nixon M2, Casazza C1, Gemmen E3, Doyle J4, Cascade E5
1Quintiles Global Consulting, Hawthorne, NY, USA, 2Quintiles, Bracknell, Berkshire, UK,
3Quintiles, Rockville, MD, USA, 4Quintiles, Hawthorne, NY, USA, 5MediGuard.org, Rockville, MD,
USA
OBJECTIVES: To assess the relationship between intent to persist (ITP) and re-
ported compliance (RC) with osteoporosis treatment versus treatment satisfaction
and its predictors. Increased persistence has been linked to improved general
health.METHODS: An online survey was administered in November 2010 to 50 US
MediGuard.org community members taking at least one osteoporosis medication.
Survey items included the Treatment Satisfaction Questionnaire for Medication
(TSQM) with 14 items across 4 domains [effectiveness (EFF), side effects (SE), con-
venience (CON), global satisfaction (GS)] and covariates such as treatment cost
(TCOST) andmedication knowledge (KNO). Using linear regression, we assessed GS
as a predictor of ITP and RC. We also explored the extent to which EFF, SE, CON,
TCOST and KNO each explained GS. The Adjusted Goodness of Fit Index (AGFI)
provided a measure of model fit. RESULTS: The tested regression model adjusting
for interaction between ITP and RC was highly significant (P  0.001) with an AGFI
of 0.79. As expected, GS was significantly and positively correlated with ITP (0.45;
t4.02) and RCwas inversely but not significantly correlatedwith ITP (-0.16; t-1.3)
and GS (-0.16;t-1.2). The inverse correlation can be explained by the wording in
the negative of the RC response scale. The TSQM domains were highly correlated
with GS: with EFF the strongest predictor (0.08; t7.6) followed by CON (0.51; t4.8)
and SE (0.47; t4.2). Finally, TCOST (-0.18; t-1.3) and KNO (0.17; t1.2) were cor-
related with GS, trending in the expected direction. CONCLUSIONS: The GS with
osteoporosis medication is dependent on effectiveness, side effects, convenience
and medication knowledge, and it impacts ITP. Opportunities exist to communi-
cate further information on these treatment attributes to patients to increase GS
and ITP. The use of patient-centric methodology in our population yielded ex-
pected relationships in a time and cost-efficient manner. A patient-centric study
correlating ITP with actual persistence should be explored.
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PILOT VALIDATION OF THE BRIEF PAIN INVENTORY ‘PAIN AT ITS WORST’
ITEM IN PATIENTS WITH RHEUMATOID ARTHRITIS
Sterling K, Naegeli AN, Zagar A
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: “Worst pain” intensity has been shown to meaningfully impact pa-
tients’ lives as indicated by a strong correlationwith functional interference scores
in rheumatoid arthritis (RA). The objective of this study was to investigate the
psychometrics of question 3, ‘pain at its worst’ of the Brief Pain Inventory Short
Form (BPI-sf Q3) in a sample of US patients with self-reported RA.METHODS: Fifty
adultswith RAwere recruited to complete questionnaires during an in-person data
collection and subsequent one-week at-home mailing. Internal consistency reli-
ability of the BPI-sf pain severity subscale (questions 1-4) was evaluated using
Cronbach’s . Test-retest reliability for BPI-sf Q3 was assessed using Intraclass
Correlation Coefficient (ICC). Pearson’s correlation coefficient was used to assess
convergent validity of the BPI-sf Q3 with the Patient Assessment of Arthritis Pain
Visual Analogue Scale (VAS). Known-groups discriminant validity was evaluated
by comparing BPI-sf Q3 mean scores using analysis of variance of RA severity and
general health, and through linear regression for number of bad physical health
days. RESULTS: Seventy-six percent participantswere female, 72%were Caucasian
with mean age (SD) 49.4 (13.2) years and mean disease duration 13.7 (12.0) years.
The mean score for BPI-sf Q3 was 6.2 (2.4) at the first session and 5.9 (2.2) at retest
with ICC 0.79. Correlation with the pain VAS was r0.79 (p.001). Cronbach’s  for
the severity subscale was 0.94. There was a non-statistically significant relation-
ship betweenmean BPI-sf Q3 and general health (p.22) and RA severity categories
(p.12); and no significant relationship with number of bad physical health days.
CONCLUSIONS: Assessment of worst pain intensity as measured by the BPI-sf
showed validity and reliability in a small sample of patients with RA and may be a
useful patient-reported outcome in clinical trials. Further validation in a larger
sample is needed to determine known-groups discriminant validity.
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SEVERE ASTHMA EXACERBATIONS ASSOCIATED WITH LONG-ACTING BETA
AGONISTS AMONG CHILDREN AND ADOLESCENTS WITH ASTHMA
Guo JJ1, Tsai K2, Kelton C1, Bian B1, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA, 2Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: The safety of long-acting beta agonists (LABAs) has been in much
debate in recent years, resulting from controversial findings reported by various
clinical and observational studies with adults. Very limited data on LABA use are
available for children and adolescentswith asthma. The objective of this study is to
assess the risk of severe asthma exacerbations (SAEs) associated with LABA use
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